Sleep surgery

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea

Retrieved on: 
Thursday, September 23, 2021
Anthony J. DeMaria, Therapy, Securities Act of 1933, Chairperson, Forensic pathology, Family medicine, Consultant, University, Program, Stanford University, Obstructive sleep apnea, SEC, Research, Science and technology in Asia, Drug Quality and Security Act, Sleep medicine, Medical director, Physician, Behavioural sciences, Adult, Sleep apnea, Awareness, Technology, Death, VIP, Dentist, Obstetrics, Pediatrics, Cardiology, OSA, Icahn School of Medicine at Mount Sinai, NASDAQ, U.S. Securities and Exchange Commission, University of Alberta, Company, Neurology, Tissue, Alberta, Apnea–hypopnea index, GLOBE, Department, Adoption, Sleep surgery, Assistant, DRS, Risk, Security (finance), Patient, Psychiatry, Securities Exchange Act of 1934, Quality of life, Snoring, Pharmaceutical industry, Dentistry, Medicine

(the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.

Key Points: 
  • (the Company or Vivos) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, announced today the official formation of the Vivos Medical Consortium.
  • For decades, the only treatment options for sleep apnea were limited and often invasive, but with the Vivos technology, that has changed dramatically.
  • Commenting on the anticipated impact of the Vivos Medical Consortium, Vivos Chairman and CEO Kirk Huntsman stated, Obstructive sleep apnea is a serious medical problem, yet it is one that, through the use of the Vivos technology, now has a highly effective medical solution that can be delivered by a dentist.
  • Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).

Top Sleep Experts Convene To Address CPAP Alternatives

Retrieved on: 
Tuesday, July 27, 2021
Sleep disorders, Medicine, Clinical medicine, Branches of biology, Continuous positive airway pressure, Mandibular advancement splint, Obstructive sleep apnea, Sleep apnea, Sleep Research Society, Osa, Sleep surgery

They will convene to discuss barriers and facilitators for adoption of non-PAP treatment approaches to obstructive sleep apnea (OSA), including Oral Appliance Therapy (OAT).

Key Points: 
  • They will convene to discuss barriers and facilitators for adoption of non-PAP treatment approaches to obstructive sleep apnea (OSA), including Oral Appliance Therapy (OAT).
  • The Sleep Research Society Foundation (SRSF) and SomnoMed put focus on non-CPAP alternatives in light of Philips recall.
  • "Our partnership with the Sleep Research Society will help bring these discussions to the forefront and treat more patients more effectively."
  • "This is a timely and important discussion about the true positioning of non-PAP treatment alternatives and the implementation aspects of such therapies," reflects Sairam Parthasarathy, MD, Board of Director, Sleep Research Society and President, Sleep Research Society Foundation.

One in Four Patients in Latest Clinical Study Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment

Retrieved on: 
Tuesday, July 13, 2021
Sleep disorders, Clinical medicine, Medicine, Branches of biology, Obstructive sleep apnea, Continuous positive airway pressure, Sleep apnea, Osa, Sleep surgery, Mandibular advancement splint

Patients who experienced little to no OSA symptoms may no longer require CPAP, neuro-stimulation, or other lifetime interventions.

Key Points: 
  • Patients who experienced little to no OSA symptoms may no longer require CPAP, neuro-stimulation, or other lifetime interventions.
  • Simply put, we believe this clinical data shows that our core technology is a game-changer for OSA sufferers who undergo the Vivos treatment.
  • A number of patients in the study remain in treatment, some of whom are also receiving CPAP therapy (except during sleep testing).
  • Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).

GM Instruments, Ltd. Announces Partnership Agreement with Sensonics International

Retrieved on: 
Wednesday, June 2, 2021
Sleep disorders, Clinical medicine, Medicine, Branches of biology, Obstructive sleep apnea, Sleep apnea, Continuous positive airway pressure, Osa, Sleep surgery, Mandibular advancement splint

This union results in the promotion, co-distribution, and co-development of equipment critical for nasal and oral measurement.

Key Points: 
  • This union results in the promotion, co-distribution, and co-development of equipment critical for nasal and oral measurement.
  • One application relates to obstructive sleep apnea (OSA), a condition experienced by 1 out of every 15 adult Americans.
  • Accurate functional measures are sorely needed to assess the effects of CPAP and other treatments for OSA on nasal function, including smell dysfunction.
  • Sensonics International, founded in 1982 by Dr. Richard L. Doty of the University of Pennsylvania, is the world's purveyor of the finest quality smell and taste products.

Sleep Apnea Devices Market Revenue to Cross USD 11.6 Bn by 2027: Global Market Insights Inc.

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Sleep disorders, Sleep apnea, Sleep, Apnea, Central sleep apnea, Sleep surgery

High adoption of technologically advanced sleep apnea devices along with the increasing number of sleep apnea disorders across the globe will stimulate the market growth.

Key Points: 
  • High adoption of technologically advanced sleep apnea devices along with the increasing number of sleep apnea disorders across the globe will stimulate the market growth.
  • The increasing geriatric population, availability of insurance coverage for treatment of sleep apnea & other sleep disorders in the U.S., and innovations in sleep apnea devices will spur the industry growth.
  • Hence, a rising prevalence of chronic conditions associated with sleep ailments is expected to surge the acceptance of sleep apnea devices .
  • The use of smartphone-based applications to monitor sleep apnea treatment hasimproved comfort and convenience in home sleep apnea treatment.

Sommetrics Receives IDE Approval From the FDA to Begin SUPRA Trial of aerSleep II for Treating Sleep Apnea

Retrieved on: 
Thursday, April 29, 2021
Health, FDA, Other Consumer, Consumer, Clinical trials, Pharmaceutical, Biotechnology, Sleep disorders, Branches of biology, Clinical medicine, Medicine, Obstructive sleep apnea, Snoring, Sleep apnea, Osa, Investigational device exemption, Sleep surgery

b'Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.

Key Points: 
  • b'Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system.
  • Sommetrics will provide additional information regarding the SUPRA trial on its website as contracts and Institutional Review Board (IRB) approvals are finalized with the study sites.
  • Sommetrics\xe2\x80\x99 aerSleep system offers a first-in-class, comfortable, silent and non-invasive option for treating OSA sufferers.
  • It is focused on improving sleep quality by providing products and services that deal with disorders of the upper airway such as obstructive sleep apnea (OSA) and snoring .

Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

Retrieved on: 
Thursday, March 25, 2021
Professional services, Health, Medical devices, Other Health, Finance, Clinical trials, Pharmaceutical, Sleep disorders, Branches of biology, Sleep, Animal physiology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep surgery, AD109, Obstructive Sleep Apnea, Apnimed

The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.

Key Points: 
  • The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.
  • The vast majority of patients want a simple and convenient solution which a daily pill taken before sleep can offer.
  • People living with Obstructive Sleep Apnea need a safe, effective, and easy-to-use treatment option that addresses the underlying neurologic cause of the disease.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center

Retrieved on: 
Monday, March 8, 2021
Branches of biology, Sleep disorders, Physiology, Hypopnea, Sleep apnea, Vivos, Mandibular advancement splint, Apnea, Sleep medicine, Obstructive sleep apnea, Sleep surgery

As part of the new sleep medicine center, patients receive treatment with the Vivos System, a clinically effective, non-surgical, non-invasive, non-pharmaceutical oral appliance treatment for mild-to-moderate sleep apnea.

Key Points: 
  • As part of the new sleep medicine center, patients receive treatment with the Vivos System, a clinically effective, non-surgical, non-invasive, non-pharmaceutical oral appliance treatment for mild-to-moderate sleep apnea.
  • The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
  • The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA.
  • The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

Signifier Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence

Retrieved on: 
Monday, March 1, 2021
Biotechnology, General Health, Health, Medical devices, Sleep disorders, Branches of biology, Animal physiology, Sleep apnea, Snoring, Obstructive sleep apnea, Sleep, Apnea, Breath: The New Science of a Lost Art, Sleep surgery, Mandibular advancement splint, Obstructive Sleep Apnea and Snoring, Signifier Medical Technologies

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA , the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN Award in the Medical category.

Key Points: 
  • Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA , the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN Award in the Medical category.
  • This award further demonstrates the value of eXciteOSA as a proven, transformative treatment for patients with a design optimized for ease of use and high functionality.
  • The GOOD DESIGN award is presented by The Chicago Athenaeum Museum of Architecture and Design and The European Centre for Architecture Art Design and Urban Studies .
  • Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep disordered breathing conditions and snoring.

Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Wednesday, February 24, 2021
Sleep disorders, Branches of biology, Obstructive sleep apnea, Clinical medicine, Sleep apnea, Medicine, Osa, Sleep surgery, Mandibular advancement splint

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA).

Key Points: 
  • Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA).
  • Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in March 2019.
  • Limited by U.S. federal law to investigational use in the United States.
  • 1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep.